Rapid increase in the incidence of end-stage renal disease in patients with type 1 diabetes having HbA1c 10% or higher for 15 years.
HbA1c
duration of diabetes
end-stage renal disease (ESRD)
follow-up period
type 1 diabetes mellitus (T1DM)
Journal
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
ISSN: 0918-5739
Titre abrégé: Clin Pediatr Endocrinol
Pays: Japan
ID NLM: 9433330
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
03
2019
accepted:
17
07
2019
entrez:
1
11
2019
pubmed:
2
11
2019
medline:
2
11
2019
Statut:
ppublish
Résumé
The incidence of end-stage renal disease (ESRD) in Japanese patients with type 1 diabetes mellitus (T1DM) was investigated regarding the association between mean HbA1c values during follow-up and the duration of follow-up/illness. The study includes 988 patients diagnosed at ages younger than 30 yr. These patients were initially examined between 1962 and 1999, and HbA1 and/or HbA1c measurements were taken for at least 3 yr after 1980. The follow-up period was from the date of the first HbA1 or HbA1c measurement to the final measurement day, or HbA1c measurement day immediately before the development of ESRD. The condition progressed to ESRD in 63 patients (mean duration of illness: 23.6 yr). Cox regression analysis revealed that patients with HbA1c of ≥ 10% had a significantly increased higher risk than those with HbA1c under 8% (P < 0.0001). The HbA1c cut-off point was 10.0%. The HbA1c value was ≥ 10% at baseline and during follow-up in 128 patients. Assuming that HbA1c of ≥ 10% persisted since the time of diagnosis in these patients, the cumulative incidence of ESRD abruptly increased after 15 yr of illness. Thus, the incidence of ESRD increased after the persistence of HbA1c of ≥ 10% for 15 yr.
Identifiants
pubmed: 31666764
doi: 10.1297/cpe.28.113
pii: 2019-0009
pmc: PMC6801355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113-125Informations de copyright
2019©The Japanese Society for Pediatric Endocrinology.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Kidney Int. 2002 Mar;61(3):1086-97
pubmed: 11849464
Lancet. 1997 Jun 21;349(9068):1787-92
pubmed: 9269212
Arch Intern Med. 2009 Jul 27;169(14):1307-16
pubmed: 19636033
J Diabetes Complications. 2004 May-Jun;18(3):155-9
pubmed: 15145326
J Diabetes Investig. 2012 Feb 20;3(1):39-40
pubmed: 24843544
Am J Med. 1995 Nov;99(5):497-504
pubmed: 7485207
J Am Soc Nephrol. 2011 Mar;22(3):545-53
pubmed: 21355053
Diabetes Care. 2014 Feb;37(2):381-8
pubmed: 24026564
Am J Kidney Dis. 2003 Jul;42(1):117-24
pubmed: 12830463
Diabetologia. 1996 May;39(5):587-93
pubmed: 8739919
Diabetes Care. 2018 Mar;41(3):420-425
pubmed: 29025877
J Am Soc Nephrol. 2009 Apr;20(4):883-92
pubmed: 19225038
JAMA. 2005 Oct 12;294(14):1782-7
pubmed: 16219881
Kidney Int. 2012 Sep;82(5):589-97
pubmed: 22622493
J Am Soc Nephrol. 2011 Mar;22(3):537-44
pubmed: 21335512
J Am Soc Nephrol. 2014 Dec;25(12):2916-25
pubmed: 24904086
Diabetes Care. 2018 Mar;41(3):434-439
pubmed: 29263163
Diabetes Care. 2002 May;25(5):859-64
pubmed: 11978681
Diabetes Care. 1999 May;22(5):743-51
pubmed: 10332675
BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000177
pubmed: 27110369
Am J Kidney Dis. 2009 Nov;54(5):810-9
pubmed: 19540640
BMJ. 1998 Sep 12;317(7160):703-13
pubmed: 9732337
Nephron. 1997;77(2):176-85
pubmed: 9346384